Boston, MA – According to filings with the U.S. Securities and Exchange Commission, EIP Pharma is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Alam played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About EIP Pharma
EIP Pharma is a clinical stage therapeutics company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. We believe the neurodegenerative process, in the early stages, is primarily comprised of neuroinflammation-induced damage to synapses, which are the interconnections between nerve cells, or neurons. Our lead product candidate, neflamapimod, is currently in clinical development as a disease-modifying treatment for neurodegenerative diseases. Our lead indication is dementia with Lewy Bodies and neflamapimod has also been evaluated in early Alzheimers disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke.

To learn more about EIP Pharma, visit http://www.eippharma.com/

Contact:
John Alam, Chief Executive Officer
617-744-4400

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved